What Happens If You Do Nothing? — Comparing Treatment With Best Supportive Care

Best supportive care (BSC) means active medical care aimed entirely at comfort — pain control, breathlessness relief, nutrition support, and emotional care — without chemotherapy, immunotherapy, or any other cancer-directed treatment. It is a recognised NCCN and ASCO care pathway, chosen deliberately, not an absence of care or a waiting room for the end.

Many families hear "no more treatment" and assume it means being sent home to wait. In practice, BSC teams actively manage symptoms as they change — adjusting pain medication, treating discomfort as it arises, and supporting nutrition — often extending comfortable, meaningful time rather than shortening it. For the fundamentals of what immunotherapy itself involves, see What Is Immunotherapy? How It Differs From Chemotherapy.

This page compares immunotherapy with best supportive care honestly — including for families who feel pressured, financially or emotionally, to keep pursuing treatment that may not be right for their situation.

Yes, for many families it is reasonable — and for most patients, this exact choice never actually arises, because most people with advanced cancer in India are not eligible for immunotherapy in the first place. Eligibility depends on a specific biomarker result, such as PD-L1 expression or MSI-High/dMMR status, and on cancer type — not on how advanced the disease is or how much a family hopes it will work.

Even among patients who are biomarker-eligible, immunotherapy is not automatically the right choice. Overall fitness, organ function, and performance status (a doctor's measure of how well someone can carry out daily activities) all affect whether treatment is likely to help more than it burdens. Pursuing treatment when these factors are poor can mean spending remaining time managing side effects and hospital visits, without a realistic chance of benefit.

Choosing best supportive care is not "giving up" — it is choosing where and how time is spent, deliberately, with your oncology team's honest input rather than a general online comparison.

1. 1

   Confirm eligibility, honestly

   Biomarker results and cancer type decide, upfront, whether immunotherapy is even an available option — this alone resolves the question for most families.

2. 2

   Assess fitness and organ function

   Performance status and how well vital organs are working affect whether treatment is likely to help more than it costs.

3. 3

   Name what matters most, out loud

   More time, staying at home, avoiding hospital visits, or giving treatment a real attempt — families rarely agree with each other until this is said plainly.

4. 4

   Consider a time-boxed trial, if eligible

   Some patients choose a defined trial of treatment with a planned review date, rather than an open-ended commitment either way.

5. 5

   Revisit the decision — it isn't permanent

   Circumstances, symptoms, and priorities can change, and the plan can change with them, in either direction.

"Doing nothing" is a misleading way to describe it — best supportive care is active, ongoing care. It typically includes regular symptom review, pain and nausea management, nutrition support, help with breathlessness, and emotional and psycho-oncology support for the patient and family. Depending on where a patient lives, this can be delivered at home, through a hospice-style service, or via clinic visits.

It also does not mean the relationship with the oncology team ends. Most centres, including CION, continue to review the patient's situation and remain available if the family's priorities or the disease's course genuinely change.

For some families, yes — and that is a legitimate factor to weigh openly, not something to feel embarrassed about. Immunotherapy typically involves recurring costs across multiple cycles, in addition to biomarker testing beforehand. Best supportive care usually costs less overall, though home nursing, medication, and nutrition support still carry real costs that vary by what a patient needs.

Any cost figures mentioned on this site are indicative only, as of August 2026, and can change. Ask your CION oncology team for a written cost estimate specific to your case — for either path — before deciding anything, including whether Aarogyasri, insurance, or EMI options apply to you.

CION's tumour board discusses best supportive care as a genuine option for every eligible patient — not a fallback mentioned only after every other option is exhausted. If your family is weighing immunotherapy against no further treatment, a free, honest conversation with our oncology team may help more than another hour of searching. See Immunotherapy at CION Cancer Clinics for the fuller picture of how immunotherapy is used and monitored here.

• What Is Immunotherapy? How It Differs From Chemotherapy — the fundamentals, if you want them before deciding.
• Immunotherapy vs Chemotherapy: Which Is Better for You? — for families still weighing between two active treatments.
• Immunotherapy Before Surgery: What Neoadjuvant Treatment Does — relevant mainly for earlier-stage disease, a different situation from the one this page addresses.

This page compares immunotherapy and best supportive care in general terms to support your conversation with an oncologist and palliative-care team — it does not recommend one path over the other for your specific case, and it does not state or imply any survival benefit for either option. Only your treating oncology team, reviewing your complete case, can advise on eligibility and the right path for your family.

Thousands of families have weighed this same choice with our team

Comparing treatment against no treatment from search results is not the same as reviewing your family's actual case with an oncologist. Take the first step today — our team walks this part of the journey with you.